Evidence map›Paper›PMID 23053645›Full record

Trial reportBreast cancer research and treatment2012

A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors.

Jill E Lavigne, Charles Heckler, Jennifer L Mathews, Oxana Palesh, Jeffrey J Kirshner, Raymond Lord, Andrew Jacobs, Eric Amos, Gary R Morrow, Karen Mustian

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2018
    Article
  12. Gabapentin for the treatment of alcohol use disorder.Expert opinion on investigational drugs · 2018
    Review
  13. Anxiety and Depression in Cancer Survivors.The Medical clinics of North America · 2017
    Review
  14. Anxiety Disorders Among Women: A Female Lifespan Approach.Focus (American Psychiatric Publishing) · 2017
    Article
  15. Article
  16. Article
  17. Psychopharmacology in cancer.Current psychiatry reports · 2015
    Review
  18. Gabapentin Therapy in Psychiatric Disorders: A Systematic Review.The primary care companion for CNS disorders · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jill E LavigneWegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, Rochester, NY 14618, USA. jlavigne@sjfc.edu
Charles Heckler
Jennifer L Mathews
Oxana Palesh
Jeffrey J Kirshner
Raymond Lord
Andrew Jacobs
Eric Amos
Gary R Morrow
Karen Mustian
University of Rochester Medical Center · USSt. John Fisher College · USStanford University · US

Funding

UNIVERSITY OF ROCHESTER--CCOP RESEARCH BASEU10CA037420 · NCI · UNIVERSITY OF ROCHESTER · PI MORROW, GARY R · 1985 to 2014
$21.1M
Cancer Control Research Training Curriculum (R25T)R25CA102618 · NCI · UNIVERSITY OF ROCHESTER · PI JANELSINS, MICHELLE C, MORROW, GARY R · 2004 to 2018
$6.7M
NCI NIH HHS R25 CA102618NCI NIH HHS U10 CA037420
6 · The paper itself

Abstract

Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.

Indexed as

SurvivorsAminesAnti-Anxiety AgentsAnxietyBreast NeoplasmsCyclohexanecarboxylic AcidsFemaleGabapentingamma-Aminobutyric AcidHumansMiddle AgedTreatment OutcomeAminesAnti-Anxiety AgentsCyclohexanecarboxylic AcidsGabapentingamma-Aminobutyric Acid

Identifiers

PMID23053645
PMCPMC4411951
OpenAlexW2076010357

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.